Department of Gastroenterological Surgery, National Kyushu Cancer Center, Fukuoka, Japan.
Department of Surgery, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Hiroshima, Japan.
Ann Surg Oncol. 2018 Oct;25(11):3280-3287. doi: 10.1245/s10434-018-6656-6. Epub 2018 Jul 26.
T4 esophageal cancer (EC) that invades the trachea or bronchus often has poorer prognosis than other T4 ECs. We investigated the long-term results of definitive chemoradiotherapy (dCRT) or induction chemoradiotherapy followed by surgery (iCRT-S) in patients with T4 EC with tracheobronchial invasion (TBI).
From 2003 to 2013, 71 patients with T4 EC with TBI were treated in our institution; 58 underwent dCRT, and 13 underwent iCRT-S. The long-term results associated with survival were retrospectively analyzed, and prognostic factors were examined by univariable and multivariable analysis.
The 1-, 2-, and 5-year overall survival for all patients with T4 EC with TBI treated by dCRT or iCRT-S was 57, 29, and 19%, respectively. Multivariable analysis revealed that clinical lymph node (LN) metastasis and the treatment period were significant prognostic factors. Clinical LN positivity had significantly poorer prognosis than LN negativity. The treatment outcome in the later period was significantly better than that in the earlier period. In particular, the outcome after dCRT revealed significantly better prognosis in the later compared with the earlier period, whereas the outcome after iCRT-S did not show such a difference. With respect to treatment modality, no significant difference in survival was observed between dCRT and iCRT-S.
Clinical LN negativity and later treatment period were significantly good prognostic factors for T4 EC with TBI. The recent improvements in dCRT outcomes may help to achieve survival comparable to that of iCRT-S.
侵犯气管或支气管的 T4 食管癌(EC)通常比其他 T4 EC 预后更差。我们研究了经根治性放化疗(dCRT)或诱导放化疗后手术(iCRT-S)治疗 T4 EC 合并气管支气管侵犯(TBI)患者的长期结果。
2003 年至 2013 年,我们机构治疗了 71 例 T4 EC 合并 TBI 患者;58 例行 dCRT,13 例行 iCRT-S。回顾性分析与生存相关的长期结果,并通过单变量和多变量分析检查预后因素。
所有接受 dCRT 或 iCRT-S 治疗的 T4 EC 合并 TBI 患者的 1、2 和 5 年总生存率分别为 57%、29%和 19%。多变量分析显示,临床淋巴结(LN)转移和治疗时期是显著的预后因素。临床 LN 阳性比 LN 阴性的预后明显差。后期的治疗效果明显优于早期。特别是,dCRT 的治疗结果在后期明显优于早期,而 iCRT-S 的治疗结果则没有表现出这种差异。关于治疗方式,dCRT 和 iCRT-S 之间的生存无显著差异。
临床 LN 阴性和治疗后期是 T4 EC 合并 TBI 的显著良好预后因素。dCRT 近期结果的改善可能有助于实现与 iCRT-S 相当的生存结果。